Sodium-glucose co-transporter-2 (SGLT2) inhibitors Target Population, Competitive Landscape, and Market Forecast report

Key Insights on SGLT2 Inhibitors

• Market size projection: As per DelveInsight’s analysis, the total market size of SGLT2 inhibitors in the 7MM is expected to demonstrate robust growth through 2034

• Market Drivers: Key market drivers of SGLT2 inhibitors include expanding therapeutic indications beyond Type 2 diabetes into heart failure and chronic kidney disease, increasing prevalence of diabetes mellitus with approximately 38 million cases in the US, growing acceptance of cardiovascular protection benefits, and supportive regulatory approvals for broader indications.

• Potential Patient Pool: The report provides the total SGLT2 inhibitors potential pool across Type 2 diabetes, chronic kidney disease, and congestive heart failure.

• Key companies: Leading SGLT2 inhibitor companies include Boehringer Ingelheim/Eli Lilly (JARDIANCE/empagliflozin), AstraZeneca (FARXIGA/dapagliflozin), Johnson & Johnson (INVOKANA/canagliflozin), TheracosBio (BRENZAVVY/bexagliflozin), and Lexicon Pharmaceuticals (INPEFA/sotagliflozin), among others.

• Pipeline assets: Key SGLT2 inhibitors in the pipeline include YG1699 (Youngene Therapeutics), JP-2266 (Jeil Pharmaceuticals), and other dual SGLT1/2 inhibitors advancing through Phase II clinical trials.

• Recent developments: Recent milestones include the expansion of JARDIANCE into the chronic kidney disease indication, and INPEFA approval showing a 23% reduction in cardiovascular deaths. The EMPA-KIDNEY trial demonstrated empagliflozin’s 28% reduction in kidney disease progression or cardiovascular death.

Access DelveInsight’s comprehensive SGLT2 Inhibitors Market Forecast 2034 report for detailed competitive analysis, pipeline assessment, and strategic business intelligence.

SGLT2 Inhibitors Market Analysis

The SGLT2 inhibitors market represents one of the most dynamic therapeutic areas in the pharmaceutical industry, driven by the unique mechanism of action that blocks sodium-glucose co-transporter-2 proteins in kidney proximal tubules to promote glucose excretion through urine. The market size has evolved from a diabetes-focused therapy to a comprehensive cardiorenal protection platform.

DelveInsight’s comprehensive Sodium-glucose co-transporter-2 (SGLT2) inhibitors Target Population, Competitive Landscape, and Market Forecast report indicates sustained expansion across the 7MM countries, with North America maintaining the largest revenue share at 40.79% in 2024. The therapeutic landscape demonstrates strong momentum in emerging markets, particularly Asia-Pacific regions, while established markets like the United States continue to drive innovation through expanded indications.

SGLT2 inhibitor potential patient pool encompasses multiple therapeutic indications with substantial patient populations across the 7MM. The report’s epidemiological segmentation demonstrates the expanding addressable patient pool beyond traditional diabetes management, with geographic segmentation showing significant treatment opportunities across different healthcare systems and reimbursement frameworks.

SGLT2 Inhibitors Competitive Landscape

The competitive landscape features established market leaders leveraging clinical evidence and expanded indications to maintain market position. Boehringer Ingelheim’s JARDIANCE (empagliflozin) dominates with 55.30% market share in 2024, supported by robust cardiovascular outcomes data and chronic kidney disease approvals. AstraZeneca’s FARXIGA (dapagliflozin) has secured significant market traction with approximately $3 billion in annual sales, benefiting from early heart failure approvals and broad therapeutic labeling. Johnson & Johnson’s INVOKANA (canagliflozin) maintains competitive positioning despite historical safety concerns, while TheracosBio’s BRENZAVVY (bexagliflozin) represents the newest FDA-approved option for glycemic control.

Current treatment options span monotherapy and combination approaches with other diabetes medications, including metformin, DPP-4 inhibitors, and insulin therapy. Drug profiles demonstrate distinct mechanisms of action, with selective SGLT2 inhibitors like empagliflozin showing the greatest selectivity compared to SGLT1, while dual SGLT1/2 inhibitors like sotagliflozin (INPEFA) provide enhanced glycemic control through intestinal glucose absorption modulation. Development milestones include empagliflozin’s kidney disease progression reduction demonstrated in the EMPA-KIDNEY trial, sotagliflozin’s 33% reduction in cardiovascular deaths and heart failure hospitalizations, and emerging pipeline candidates advancing through Phase II trials.

Commercial arrangements include strategic collaborations between major pharmaceutical companies, with Boehringer Ingelheim partnering with Eli Lilly for JARDIANCE development and marketing. Licensing deals encompass regional partnerships for market access, particularly in emerging markets where local regulatory expertise becomes critical for successful product launches. Pipeline development focuses on dual SGLT1/2 inhibition strategies, with companies like Youngene Therapeutics and Jeil Pharmaceuticals advancing novel compounds targeting enhanced glycemic control and improved glomerular filtration benefits.

Know which company has the competitive advantagein this landscape @ SGLT2 inhibitor Competitive Landscape

SGLT2 Inhibitors Market Drivers and Barriers

Unmet medical needs drive significant market opportunities as healthcare providers seek comprehensive cardiorenal protection beyond glucose control. The growing recognition of SGLT2 inhibitors’ cardiovascular benefits, including reduced heart attack, stroke, and cardiovascular death rates, addresses critical treatment gaps in high-risk patient populations. Clinical evidence demonstrates natriuretic and osmotic diuretic effects providing cardiovascular protection through reduced cardiac preload and afterload, improved myocardial energetics, and enhanced vascular function.

Additional market drivers include expanding therapeutic indications with ongoing research exploring applications in obesity, NASH, and PCOS conditions, creating substantial growth opportunities beyond traditional diabetes management. The increasing elderly population represents a highly vulnerable demographic for chronic diseases, driving demand for advanced medications with proven multi-organ protection benefits. Government initiatives supporting mass screening programs for diabetes and cardiovascular disease detection contribute to earlier diagnosis and treatment initiation, expanding the addressable patient population significantly.

Healthcare provider acceptance continues growing as clinical guidelines increasingly recommend SGLT2 inhibitors for cardiovascular risk reduction, with American Diabetes Association and KDIGO guidelines supporting their use across multiple therapeutic areas. The development of next-generation dual SGLT1/2 inhibitors offers enhanced efficacy profiles, addressing limitations of selective SGLT2 inhibition while providing additional intestinal glucose absorption benefits.

Dive deeper into the SGLT2 inhibitors market opportunities, competitive positioning, and business development strategies.

Key Opinion Leader Perspective:

“Meta-analyses and reviews confirm that the benefits of SGLT2 inhibitors reduced all-cause mortality, cardiovascular death, and hospitalization for heart failure,” according to MD, PhD from Harvard Medical School/Dana-Farber Cancer Institute. Clinical experts emphasize the natriuretic and osmotic diuretic effects as key drivers of cardiovascular protection, helping reduce cardiac preload and afterload while improving myocardial energetics and vascular function.

Know what key opinion leaders are aying about SGLT2 inhibitor therapies @ KOL views on SGLT2 inhibitor.

DelveInsight’s Analysis:

DelveInsight’s pharmaceutical market research indicates SGLT2 inhibitors represent a paradigm shift in chronic disease management, with expanding therapeutic applications driving sustained market growth through 2034. The convergence of robust clinical evidence, regulatory support, and unmet medical needs positions this therapeutic class as a cornerstone for healthcare executives seeking long-term value creation in cardiorenal therapeutics.

Conclusion

The SGLT2 inhibitors market stands at the forefront of pharmaceutical innovation, transforming from diabetes-focused therapy to a comprehensive cardiorenal protection platform. With market expansion driven by proven cardiovascular benefits, expanding indications, and robust pipeline development, the therapeutic area represents significant opportunities for healthcare executives seeking sustainable growth in chronic disease management. The convergence of demographic trends, clinical evidence, and regulatory support positions SGLT2 inhibitors as cornerstone therapies for multiple chronic conditions affecting millions of patients globally.

Scope of the SGLT2 Inhibitor Market Report

• Comprehensive Geographic Coverage: Analysis spans the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan with detailed market sizing and forecasting from 2020-2034

• Epidemiological Segmentation: Total cases in selected indications for SGLT2 inhibitors, eligible patient pool analysis, and treated cases segmentation across therapeutic areas

• Competitive Intelligence: Detailed profiles of marketed drugs including INVOKANA, FARXIGA/FORXIGA, JARDIANCE, BRENZAVVY, and emerging pipeline candidates with Phase III and Phase II development status

• Market Analysis Framework: Regional therapy segmentation, Key Opinion Leader perspectives, SWOT analysis, reimbursement landscapes, and conjoint analysis of approved and emerging therapies

• Clinical Development Insights: Pipeline development activities including designation tracking, collaborations, acquisitions, licensing agreements, and patent details for emerging SGLT2 inhibitor therapies

• Strategic Business Intelligence: Treatment practice analysis, unmet medical needs assessment, market attractiveness evaluation, and qualitative analysis supporting business development decisions

• Financial and Commercial Analysis: Eleven-year market forecast with drug uptake assumptions, market opportunity assessment, cost-effectiveness scenarios, and accessibility insights across different healthcare systems

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of SGLT2 Inhibitor

4. Key Events

5. SGLT2 Inhibitor Epidemiology Market Forecast Methodology

6. SGLT2 Inhibitor Market Overview at a Glance in the 7MM

7. SGLT2 Inhibitor: Background and Overview

8. Epidemiology and SGLT2 Inhibitor Patient Population in Different Indications

9. SGLT2 Inhibitor Target Patient Pool

10. SGLT2 Inhibitor Marketed Therapies

11. SGLT2 Inhibitor Emerging Therapies

12. SGLT2 Inhibitor: Seven Major Market Analysis

13. SGLT2 Inhibitor SWOT Analysis

14. KOL Views

15. SGLT2 Inhibitor Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services